- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 14.08. | MapLight dims preclinical programs to make phase 3-ready schizophrenia drug shine brighter | 2 | FierceBiotech | ||
| 13.08. | MapLight Therapeutics, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 13.08. | MapLight Therapeutics, Inc. GAAP EPS of -$1.32 misses by $0.01 | 1 | Seeking Alpha | ||
| 13.08. | MapLight Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 13.08. | MapLight Therapeutics secures $150M in PIPE funding | 2 | Seeking Alpha | ||
| MAPLIGHT THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 13.08. | MapLight Therapeutics sichert sich 150 Millionen Dollar durch Privatplatzierung | 2 | Investing.com Deutsch | ||
| 13.08. | MapLight Therapeutics raises $150 million in private placement | 2 | Investing.com | ||
| 13.08. | MapLight Therapeutics, Inc.: MapLight Therapeutics Announces $150 Million Private Placement Financing | 1.926 | GlobeNewswire (Europe) | SAN FRANCISCO and BOSTON, Aug. 13, 2026 (GLOBE NEWSWIRE) -- MapLight Therapeutics, Inc. (Nasdaq: MPLT), a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering... ► Artikel lesen | |
| 29.07. | MapLight CEO on what investors missed in the biotech's schizophrenia data | 3 | BioPharma Dive | ||
| 28.07. | MapLight Therapeutics recovers a portion of Monday's 73% rout | 1 | Seeking Alpha | ||
| 28.07. | BMO cuts MapLight Therapeutics price target on trial results | 2 | Investing.com | ||
| 28.07. | Canaccord cuts MapLight Therapeutics stock price target on trial data | 2 | Investing.com | ||
| 28.07. | H.C. Wainwright cuts MapLight Therapeutics stock price target on trial results | 3 | Investing.com | ||
| 27.07. | Morgan Stanley downgrades MapLight Therapeutics stock rating on trial results | 21 | Investing.com | ||
| 27.07. | Enttäuschende Studiendaten: Morgan Stanley stuft MapLight Therapeutics ab | 9 | Investing.com Deutsch | ||
| 27.07. | Wolfe cuts MapLight Therapeutics stock price target on trial data | 2 | Investing.com | ||
| 27.07. | MapLight dives despite positive data for schizophrenia drug | 2 | BioPharma Dive | ||
| 27.07. | MapLight shares sink on mixed phase 2 schizophrenia readout | 1 | FierceBiotech | ||
| 27.07. | MapLight Therapeutics Stock Falls Despite Schizophrenia Drug Meeting Main Trial Goal | 1 | Benzinga.com | ||
| 27.07. | MapLight Therapeutics: TD Cowen bestätigt Kaufempfehlung nach Studiendaten | 3 | Investing.com Deutsch |
1 2 3 4 Weiter >>
68 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| AMGEN | 371,90 | -0,35 % | Amgen: Tezspire Demonstrates Positive Phase 3 Results In Eosinophilic Esophagitis Across Both Co-primary And All Key Secondary Endpoints | Statistically Significant and Clinically Meaningful Disease and Symptom Improvements Compared to Placebo Maintained Through Week 52
Efficacy in a Third Epithelial-Driven... ► Artikel lesen | |
| CRISPR THERAPEUTICS | 49,360 | -0,85 % | CRISPR Therapeutics legt positive Einjahresdaten für Gentherapie CTX310 vor | ||
| INOVIO PHARMACEUTICALS | 1,070 | -3,60 % | INOVIO Pharmaceuticals, Inc.: INOVIO Reports Second Quarter 2026 Financial Results and Recent Business Highlights | U.S. Food and Drug Administration (FDA) review of Biologics License Application (BLA) for INO-3107 as a treatment for Recurrent Respiratory Papillomatosis (RRP)... ► Artikel lesen | |
| INFLARX | 1,950 | +1,99 % | InflaRx: Revolutionäre Therapieansätze könnten alles verändern | ||
| INTELLIA THERAPEUTICS | 11,220 | +0,90 % | Cathie Wood's ARK buys Intellia stock, sells Roblox | ||
| NUREXONE BIOLOGIC | 0,349 | +4,18 % | Keine von der FDA zugelassene Exosomentherapie: Warum NurExone eine große Marktchance adressiert | ||
| IBIO | 1,163 | 0,00 % | iBio, Inc.: iBio Reports Fiscal Year 2026 Financial Results and Provides Corporate Update | SAN DIEGO, Aug. 28, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ: IBIO), a clinical-stage biotechnology company developing long-acting antibody therapeutics for obesity, cardiometabolic and cardiopulmonary... ► Artikel lesen | |
| GERON | 1,317 | +1,35 % | Geron Corporation: Geron Announces Appointment of Chinmaya Rath as Chief Business Officer | FOSTER CITY, Calif., July 13, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer... ► Artikel lesen | |
| IMMUNITYBIO | 6,880 | -1,01 % | XETR NEW INSTRUMENTS AVAILABLE ON XETRA - 04.06.2026 | Folgende Wertpapiere werden in den Handel an folgenden Handelsplätzen (MIC Code) im Quotation Board an der Frankfurter Wertpapierbörse (FWB) aufgenommen. Die Notierung an anderen Handelsplätzen im Quotation... ► Artikel lesen | |
| IMMATICS | 8,260 | +1,29 % | Immatics Announces $150 Million Underwritten Offering | Houston, Texas and Tuebingen, Germany, August 25, 2026 - Immatics N.V. (NASDAQ: IMTX, "Immatics" or the "Company"), the global leader in precision targeting of PRAME with multiple clinical-stage programs... ► Artikel lesen | |
| MYRIAD GENETICS | 2,727 | +0,44 % | Myriad Genetics, Inc.: Myriad Genetics Reports Second Quarter 2026 Financial Results; Deploying New Initiatives Focused on Driving Increased Efficiency, Productivity and Scalability | Highlights Second quarter 2026 revenue of $190.7 million decreased 11% year-over-year, reflecting a 1% decline in volume and a 9% decrease in average revenue per test year-over-year. The company is... ► Artikel lesen | |
| MANNKIND | 3,395 | 0,00 % | MannKind-Aktie: Biotech-Chance mit neuen Wachstumstreibern | Die MannKind-Aktie steht nach zwei wichtigen FDA-Zulassungen vor einer neuen Wachstumsphase. Bei einer Marktkapitalisierung von rund 1,24 Milliarden US-Dollar könnte der Markt das langfristige Potenzial... ► Artikel lesen | |
| GINKGO BIOWORKS | 6,064 | +0,66 % | Ginkgo Bioworks Reports First Quarter 2026 Financial Results, Completes Divestiture of Biosecurity and Continues to Scale Autonomous Lab | Ginkgo provides an update on its first quarter financial results following the divestiture of its Biosecurity business
BOSTON, May 7, 2026 /PRNewswire/ -- Ginkgo... ► Artikel lesen | |
| IMMUNIC | 13,485 | -2,56 % | EQS-News: Immunic AG: Immunic, Inc. Reports Second Quarter 2026 Financial Results and Provides Corporate Update | Issuer: Immunic AG
/ Key word(s): Quarter Results
Immunic, Inc. Reports Second Quarter 2026 Financial Results and Provides Corporate Update
11.08.2026 / 12:30 CET/CEST
The... ► Artikel lesen | |
| IOVANCE BIOTHERAPEUTICS | 6,910 | -0,29 % | TD Cowen raises Iovance Biotherapeutics price target on sales outlook |
MAPLIGHT THERAPEUTICS INC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell +0,08 % bei einem Aktienkurs von 12,610 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu MAPLIGHT THERAPEUTICS INC finden Sie auf Wallstreet Online.